Ultragenyx Pharma (RARE) Misses Q1 EPS by 8c

Ultragenyx Pharma (NASDAQ: RARE) reported Q1 EPS of ($1.82), $0.08 worse than the analyst estimate of ($1.74). Revenue for the quarter came in at $18.2 million versus the consensus estimate of $18.3 million.

For earnings history and earnings-related data on Ultragenyx Pharma (RARE) click here.

You May Also Be Interested In

• After-Hours Movers: AVGO, SNOW, HPE, NTAP, NTSK, CHPT, FIVE, TLYS, PVH, RARE
• C3.ai (AI) Tops Q1 EPS by 5c; Offers Guidance
• Methode Electronics (MEI) Tops Q1 EPS by 2c; offers guidance